News

eHealth: Where IT meets biotech
Enlarge image

Event ReviewEUGermany

eHealth: Where IT meets biotech

16.02.2016 - The application of digital technology in the pharmaceutical and biotechnology sector was the focal point of the 9th Berlin Conference on IP in Life Sciences. According to the 100+ expert attendees, the potential of new technologies was raised through the cooperation of IT and life science specialists.

Thilo Kaltenbach’s analyse is conclusive, “The large pharma companies are rebooting their medical tools and equipment.” The management consultant from Roland Berger was one of the many experts, who highlighted in mid-February at the Berlin Conference on IP in Life Sciences "Digital Health Solutions", the factors that play an important role in E-health applications.

Pharmaceutical and biotech companies are currently sticking to the motto "Service beyond the pill", in particular on new sales and marketing scenarios based on apps and applicators. But in Kaltenbach’s opinion, that’s just the sidelines: "No one knows what ideas will establish themselves in the end. Therefore a large company is highly unlikely to go out on a limb. There is a lot of cooperating and experimenting."

Sanofi presented the issue of E-health from a Big pharma perspective at the annual BIOCOM event. Vice President Francois Nicolas, joint-responsible for diabetes management, stressed at the conference held in the French Embassy in Berlin-Mitte, the diversity of actors in the market and why pharma relies on partnerships with IT giants such as IBM, Qualcomm, Apple or Alphabet. According to Nicolas: "We are currently entering a new era of health management. We need to simplify the patient’s dealings with the disease in everyday life, so that the therapies can be used effectively." Digital solutions, particularly in common diseases such as diabetes, are currently in vogue.

Further sessions at the conference emphasised the significance of digital solutions for the research and development work. Manuel Gea from Bio-Modeling Systems in Paris pointed out, among other things, the unreliability of published data and the need for Smart Data instead of Big Data. The insufficient development of new active substances in many years of clinical trials and patient’s increasing easy access to information was once again the focal point for Roland Brus, the founder of the online platform Mytomorrows. The legal experts from Vossius, among others, informed the attendees why, under certain conditions, software is patentable and which formulations are to be observed.

A pitching session was held at the end of the day. Six invited entrepreneurs from all over Europe presented their business ideas to a jury of investors. In the end, the Bayer Accelerator Berlin-based start-up, Viomedo was the one to convince the jury. The online marketplace aims to bring drug developers and patients together to push-start clinical trials as early and as soon as possible. The crowd favourite, however, was the Spanish firm Mint Labs, which has developed a cloud-based solution for the evaluation of neurobiological MRI scans.

 

© european-biotechnology-news.com/ml+jc

http://www.european-biotechnology-news.com/news/news/2016-01/ehealth-where-it-meets-biotech.html

AwardFinlandEU

27.05.2016 The Finnish Technology Academy has awarded US-American innovator Frances Arnold the 2016 Millennium Technology Prize, worth €1m. Arnold is a pioneer in the field of directed evolution.

OncologyUK

26.05.2016 BigDNA relaunches as Iceni Pharmaceuticals with the aim to develop repurposed and reformulated cancer therapies. First order of business: repurpose Merck Serono’s cilengitide as a multiple myeloma treatment.

MicrobiomeFranceDenmarkEU

24.05.2016 One of the pioneering companies developing pharmaceuticals and diagnostics based on the gut microbiome, Enterome Bioscience, has raised €14.5m in a Series C financing round. Among the investors were Seventure and Lundbeckfond as well as Nestlé.

AntibioticsEUUKItaly

20.05.2016 The long awaited global review on antimicrobial resistance by economist Lord Jim O’Neill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics to be used before antibiotics are prescribed.

LicensingGermanyIrelandSwitzerland

18.05.2016 Bayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.

M&AGermany

17.05.2016 Newly rebranded Siemens Healthcare has entered the field of molecular testing for cancers with the acquisition of Cologne-based NEO New Oncology.

FinancingUK

11.05.2016 Newly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of age-related disease. It is the largest financing for an Oxford spin-out – or any UK academic spin-out – to date.

FinancingSwitzerland

09.05.2016 Swiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimer’s disease. The news follows a recently announced R&D collaboration with Biogen.

FinancingSpain

04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

Open InnovationFrance

03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Aachen

Biomedica 2016

Basel (CH)

Chemspec Europe 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • PLETHORA (UK)3.38 GBP12.67%
  • ALMIRALL (E)14.43 EUR7.93%

FLOP

  • 4SC (D)2.59 EUR-20.31%
  • NEUROVIVE PHARMACEUTICAL AB (S)5.25 SEK-4.55%
  • FORMYCON (D)20.15 EUR-4.37%

TOP

  • GALAPAGOS (B)51.86 EUR30.7%
  • NICOX (F)11.00 EUR28.7%
  • GENMAB (DK)1177.00 DKK22.2%

FLOP

  • MOBERG PHARMA (S)38.00 SEK-21.8%
  • 4SC (D)2.59 EUR-21.5%
  • FORMYCON (D)20.15 EUR-18.0%

TOP

  • KARO BIO (S)30.60 SEK1981.6%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • NICOX (F)11.00 EUR491.4%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)5.25 SEK-89.0%
  • BB BIOTECH (D)44.03 EUR-84.5%
  • BIOTEST (D)17.15 EUR-78.1%

No liability assumed, Date: 28.05.2016